MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We speculate that partial suppression of Mcl-1 and Bcl-xL by nilotinib was likely sufficient to lower the apoptotic threshold and sensitize CML cells to nutlin3a-induced cell death, although the mechanism associated with nilotinib's activity in the Bcr-Abl-mutant samples remains to be fully elucidated.